NO20090769L - Metode for screening av forbindelser med anti-amyloid egenskaper - Google Patents

Metode for screening av forbindelser med anti-amyloid egenskaper

Info

Publication number
NO20090769L
NO20090769L NO20090769A NO20090769A NO20090769L NO 20090769 L NO20090769 L NO 20090769L NO 20090769 A NO20090769 A NO 20090769A NO 20090769 A NO20090769 A NO 20090769A NO 20090769 L NO20090769 L NO 20090769L
Authority
NO
Norway
Prior art keywords
screening compounds
amyloid properties
amyloid
properties
screening
Prior art date
Application number
NO20090769A
Other languages
English (en)
Inventor
Hoau-Yan Wang
Philippe Morain
Caryn Thibierge
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20090769L publication Critical patent/NO20090769L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

Oppfinnelsen angår en metode for screening av forbindelser som har anti-amyloide egenskaper. Metoden for screening av forbindelser som er i stand til å dissosiere eller forhindre høy-affinitetskomplekser mellom ?-amyloidpeptider og nikotinacetylkolinreseptorer fra menneskelig hjernebarkvev gjør det mulig å raskt identifisere forbindelser ment for helbredende og/eller forebyggende behandling av nevrodegenerative sykdommer, spesielt Alzheimers sykdom.
NO20090769A 2006-08-18 2009-02-18 Metode for screening av forbindelser med anti-amyloid egenskaper NO20090769L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0607385A FR2905009A1 (fr) 2006-08-18 2006-08-18 Methode de criblage de composes aux proprietes anti-amyloide
PCT/FR2007/001372 WO2008020131A1 (fr) 2006-08-18 2007-08-16 Méthode de criblage de composes aux propriétés anti-amyloide

Publications (1)

Publication Number Publication Date
NO20090769L true NO20090769L (no) 2009-02-18

Family

ID=38157874

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090769A NO20090769L (no) 2006-08-18 2009-02-18 Metode for screening av forbindelser med anti-amyloid egenskaper

Country Status (14)

Country Link
US (1) US20100197740A1 (no)
EP (1) EP2051994A1 (no)
JP (1) JP2010505089A (no)
KR (1) KR20090047532A (no)
CN (1) CN101506231A (no)
AU (1) AU2007285666A1 (no)
BR (1) BRPI0715890A2 (no)
CA (1) CA2661122A1 (no)
EA (1) EA200900149A1 (no)
FR (1) FR2905009A1 (no)
MA (1) MA30648B1 (no)
MX (1) MX2009001591A (no)
NO (1) NO20090769L (no)
WO (1) WO2008020131A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
WO2011072257A2 (en) * 2009-12-10 2011-06-16 The Regents Of The University Of California Amyloid binding agents
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
WO2014012054A1 (en) * 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
MY194462A (en) 2016-11-25 2022-11-30 Genuv Inc Composition for Promoting Differentiation of and Protecting Neural Stem Cells and Method for Inducing Neural Regeneration using same
EA038404B1 (ru) * 2017-03-22 2021-08-23 Дженув Инк. Применение траметиниба для лечения нейродегенеративного заболевания, вызванного утратой или повреждением нейронов

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
WO1999062505A2 (en) * 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
FR2793245B1 (fr) * 1999-05-05 2002-10-11 Adir Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CN101506231A (zh) 2009-08-12
JP2010505089A (ja) 2010-02-18
US20100197740A1 (en) 2010-08-05
CA2661122A1 (fr) 2008-02-21
FR2905009A1 (fr) 2008-02-22
KR20090047532A (ko) 2009-05-12
BRPI0715890A2 (pt) 2015-06-16
WO2008020131A1 (fr) 2008-02-21
EP2051994A1 (fr) 2009-04-29
MX2009001591A (es) 2009-02-23
AU2007285666A1 (en) 2008-02-21
EA200900149A1 (ru) 2009-12-30
MA30648B1 (fr) 2009-08-03

Similar Documents

Publication Publication Date Title
NO20061765L (no) Anti-symmetrerte elektromagnetiske malinger
DK2152663T3 (da) Tri-aryl-forbindelser og sammensætninger, der omfatter dem
EA200970580A1 (ru) Таннат разагилина
WO2013023732A8 (de) Ternesit als anreger für latent-hydraulische und puzzolanische materialien
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
NO20080784L (no) Histondeacetylaseinhibitorer
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
GB2461651B (en) Determination of gas saturation radial profile from multi-frequency NMR data
NO20081160L (no) Benzimidazoltiofen forbindelser
ATE496933T1 (de) Reines rocuroniumbromid
WO2009071524A3 (en) Indolinone derivatives and process for their manufacture
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
MX2009008660A (es) Metodo para la preparacion de derivados de trifenilbuteno terapeuticamente valiosos.
WO2010008543A9 (en) Molecular signatures for diagnosing scleroderma
NO20074739L (no) Amidderivater som ionkanalligander og farmasoytiske sammensetninger og fremgangsmater for anvendelse av samme
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
NO20053210L (no) Linneslakkompensator.
DK1866433T3 (da) Fremgangsmåde til identifikation af LRRK-2interagerende molekyler og til rensning af LRRK2
NO20091999L (no) MAPK/ERK kinase inhibitorer
ATE520314T1 (de) Süssmittelzusammensetzungen
DK2203457T3 (da) Dispiro-1,2,4-trioxolaner som antimalariamidler
ATE503759T1 (de) 7-ä2-ä4-(6-fluor-3-methyl-1,2-benzisoxazol-5-yl - 1-piperazinylüethylü-2-(1-propinyl)-7h-pyrazolo
WO2009103061A3 (en) Methods and compositions for identifying, diagnosing, and treating neuroblastoma
DK1893030T3 (da) Fremgangsmåde til fremstilling af fødevarer ved ko-ekstrudering, især pølser, og fødevarer, der opnås ved denne fremgangsmåde
WO2009025761A3 (en) Methods for identifying bacterial strains that produce l-tyrosine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application